Angiotensin II regulates growth of the developing papillas ex vivo.
We tested the hypothesis that lack of angiotensin (ANG) II production in angiotensinogen (AGT)-deficient mice or pharmacologic antagonism of ANG II AT(1) receptor (AT(1)R) impairs growth of the developing papillas ex vivo, thus contributing to the hypoplastic renal medulla phenotype observed in AGT- or AT(1)R-null mice. Papillas were dissected from Hoxb7(GFP+) or AGT(+/+), (+/-), (-/-) mouse metanephroi on postnatal day P3 and grown in three-dimentional collagen matrix gels in the presence of media (control), ANG II (10(-5) M), or the specific AT(1)R antagonist candesartan (10(-6) M) for 24 h. Percent reduction in papillary length was attenuated in AGT(+/+) and in AGT(+/-) compared with AGT(-/-) (-18.4 ± 1.3 vs. -32.2 ± 1.6%, P < 0.05, -22.8 ± 1.3 vs. -32.2 ± 1.6%, P < 0.05, respectively). ANG II blunted the decrease in papilla length observed in respective media-treated controls in Hoxb7(GFP+) (-1.5 ± 0.3 vs. -10.0 ± 1.4%, P < 0.05) or AGT(+/+), (+/-), and (-/-) papillas (-12.8 ± 0.7 vs. -18.4 ± 1.3%, P < 0.05, -16.8 ± 1.1 vs. -23 ± 1.2%, P < 0.05; -26.2 ± 1.6 vs. -32.2 ± 1.6%, P < 0.05, respectively). In contrast, percent decrease in the length of Hoxb7(GFP+) papillas in the presence of the AT(1)R antagonist candesartan was higher compared with control (-24.3 ± 2.1 vs. -10.5 ± 1.8%, P < 0.05). The number of proliferating phospho-histone H3 (pH3)-positive collecting duct cells was lower, whereas the number of caspase 3-positive cells undergoing apoptosis was higher in candesartan- vs. media-treated papillas (pH3: 12 ± 1.4 vs. 21 ± 2.1, P < 0.01; caspase 3: 3.8 ± 0.5 vs. 1.7 ± 0.2, P < 0.01). Using quantitative RT-PCR, we demonstrate that AT(1)R signaling regulates the expression of genes implicated in morphogenesis of the renal medulla. We conclude that AT(1)R prevents shrinkage of the developing papillas observed ex vivo via control of Wnt7b, FGF7, β-catenin, calcineurin B1, and α3 integrin gene expression, collecting duct cell proliferation, and survival.
Division of Pediatric Nephrology, Department of Pediatrics, Hypertension, and Renal Center of Excellence, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.
Renfang
R
Song
Graeme
G
Preston
Ali
A
Khalili
Samir S
SS
El-Dahr
Ihor V
IV
Yosypiv
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology*; D000808:Angiotensinogen / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism*; D017209:Apoptosis / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D018398:Homeodomain Proteins / Q000235:genetics / Q000378:metabolism; D007679:Kidney Medulla / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D023421:Models, Animal; D009024:Morphogenesis / Q000187:drug effects; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology
D001562:Benzimidazoles; D001713:Biphenyl Compounds; D018398:Homeodomain Proteins; C093253:Hoxb7 protein, mouse; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D000808:Angiotensinogen; D000804:Angiotensin II; C081643:candesartan